NCT06098599View on ClinicalTrials.gov

Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

February 9, 2023

Study Completion Date

February 9, 2023

Conditions
Advanced Breast Cancer
Interventions
DRUG

Doxorubicin hydrochloride liposome injection

Doxorubicin hydrochloride liposome injection was administered intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial. Doxorubicin hydrochloride liposome injection was diluted with 250mL 5% glucose injection.

Trial Locations (1)

Unknown

The Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY